CS
ABCL icon

Credit Suisse’s AbCellera Biologics ABCL Stock Holding History

Credit Suisse’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$20.6M Sell
4,547,315
-30,935
-0.7% -$158K 0.02% 625
2023
Q4 		$26.1M Buy
4,578,250
+5,273
+0.1% +$24.4K 0.03% 584
2023
Q3 		$21M Sell
4,572,977
-1,609
-0% -$9.79K 0.02% 626
2023
Q2 		$29.6M Sell
4,574,586
-33,574
-0.7% -$229K 0.03% 554
2023
Q1 		$34.7M Buy
4,608,160
+507,665
+12% +$4.61M 0.04% 515
2022
Q4 		$41.5M Sell
4,100,495
-976
-0% -$11.3K 0.04% 450
2022
Q3 		$40.6M Buy
4,101,471
+1,507,513
+58% +$16.5M 0.05% 441
2022
Q2 		$27.6M Sell
2,593,958
-60,756
-2% -$514K 0.03% 581
2022
Q1 		$25.9M Buy
2,654,714
+32,389
+1% +$307K 0.02% 680
2021
Q4 		$37.5M Sell
2,622,325
-180,086
-6% -$2.73M 0.02% 777
2021
Q3 		$56.2M Buy
2,802,411
+166,638
+6% +$2.95M 0.03% 595
2021
Q2 		$58M Buy
2,635,773
+364,973
+16% +$10.1M 0.03% 606
2021
Q1 		$77.1M Buy
+2,270,800
New +$90.5M 0.04% 527

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Credit Suisse's ABCL Position: Q1 2024 in Review

Credit Suisse reduced its AbCellera Biologics (ABCL) stake by 0.68% in Q1 2024, selling an estimated $158K and leaving 4,547,315 shares worth $20.6M. The position accounts for 0.02% of the portfolio, ranked #625.

Credit Suisse first reported a position in ABCL in Q1 2021 and has held it in 13 quarters since. The position peaked at $77.1M in Q1 2021. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • Credit Suisse held 4,547,315 shares of AbCellera Biologics worth $20.6M as of Q1 2024.
  • Credit Suisse sold 30,935 AbCellera Biologics shares in Q1 2024, an estimated $158K.
  • AbCellera Biologics made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #625 holding.
  • Credit Suisse first reported a position in AbCellera Biologics in Q1 2021 and has held it in 13 quarters since.
  • Credit Suisse's AbCellera Biologics position peaked at $77.1M in Q1 2021.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.